Ionis Pharmaceuticals, Inc.

Ionis Pharmaceuticals, Inc. is a commercial-stage biotechnology company that focuses on developing RNA-targeted medicines. The company offers several approved products, including TRYNGOLZA for reducing triglyceride levels in adults with familial chylomicronemia syndrome (FCS) and acute pancreatitis, DAWNZERA for prophylaxis to prevent attacks of hereditary angioedema in adults, WAINUA for treating polyneuropathy of hereditary transthyretin-medicated amyloidosis (ATTRv-PN) in adults, SPINRAZA for pediatric and adult patients with spinal muscular atrophy (SMA), QALSODY for amyotrophic lateral sclerosis (ALS), TEGSEDI for ATTRv-PN, and WAYLIVRA for FCS and familial partial lipodystrophy. Additionally, Ionis has a robust pipeline with products in Phase 3 clinical trials, such as Olezarsen for hypertriglyceridemia and cardiovascular disease, Zilganerse for Alexander disease, and ION582 for a rare genetic neurological disease. Other pipeline candidates include Eplontersen, Pelacarsen, Bepirovirsen, and Sefaxersen targeting various conditions.

Ionis Pharmaceuticals, Inc. is listed on the Nasdaq Global Select Market (NasdaqGS) under the ticker symbol IONS. The company's stock is traded in United States Dollars (USD), which is the official currency of the United States. As a US-based company, its financial reporting and stock transactions are conducted in USD, making it accessible to investors trading on US exchanges.

Ionis Pharmaceuticals, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. Biotechnology companies like Ionis use biological processes and living organisms to develop medical treatments. In Ionis's case, the focus is on RNA-targeted medicines, which are innovative therapies that modulate gene expression at the RNA level to treat a variety of diseases, including rare genetic disorders and chronic conditions.

Ionis Pharmaceuticals, Inc. is headquartered in the United States and primarily serves the US market, as indicated by its country and region being listed as 'United States' and 'us'. The company's approved products, such as SPINRAZA, TEGSEDI, and WAYLIVRA, are available to patients in the US. While the company's description focuses on its US operations, its pipeline and products may have global potential, but specific international markets are not detailed in the available data.

Ionis Pharmaceuticals has a diverse portfolio of approved products and a robust pipeline. Approved products include TRYNGOLZA (for FCS), DAWNZERA (for hereditary angioedema), WAINUA (for ATTRv-PN), SPINRAZA (for SMA), QALSODY (for ALS), TEGSEDI (for ATTRv-PN), and WAYLIVRA (for FCS and familial partial lipodystrophy). The pipeline features Phase 3 candidates: Olezarsen for hypertriglyceridemia and cardiovascular disease, Zilganerse for Alexander disease, and ION582 for a rare genetic neurological disease. Other notable pipeline drugs include Eplontersen (targeting TTR mRNA), Pelacarsen (reducing lipoprotein(a)), Bepirovirsen (for hepatitis B), and Sefaxersen (for complement factor B reduction). These products and candidates demonstrate Ionis's focus on RNA-targeted therapies for a range of serious diseases.